angiogenesi
multistep
process
regul
proand
antiangiogen
factor
inhibit
angiogenesi
potenti
anti
cancer
treatment
strategi
investig
clinic
addit
advanc
understand
angiogen
process
led
develop
new
angiogenesi
therapi
ischem
heart
diseas
current
research
search
object
measur
indic
pharmacolog
respons
proand
antiangiogen
drug
therefor
great
interest
techniqu
visual
angiogenesi
noninvas
select
express
angiogen
blood
vessel
serv
target
molecular
imag
tracer
noninvas
visual
angiogen
process
anim
model
patient
overview
current
use
target
molecular
imag
probe
noninvas
visual
angiogenesi
given
angiogenesi
format
new
blood
vessel
exist
one
play
essenti
role
embryon
develop
howev
vascular
network
fulli
deploy
angiogenesi
trigger
local
transient
specif
condit
wellknown
patholog
condit
angiogenesi
play
role
myocardi
infarct
cancer
current
potenti
patholog
role
angiogenesi
atherosclerot
plaqu
investig
solid
tumor
angiogenesi
caus
growth
new
capillari
necessari
continu
suppli
oxygen
nutrient
tumor
tissu
allow
tumor
grow
beyond
certain
size
metastas
myocardi
infarct
mi
howev
angiogenesi
play
much
benign
role
allow
neovascular
follow
myocardi
ischemia
reason
therapeut
myocardi
angiogenesi
explor
therapeut
option
ischem
heart
diseas
neovascular
atherosclerot
plaqu
contribut
develop
plaqu
increas
risk
ruptur
clinic
complic
atherosclerosi
exampl
mi
stroke
mainli
caus
thrombu
format
result
ruptur
atherosclerot
plaqu
exposur
tissu
factor
blood
atherosclerot
plaqu
form
platelet
adher
subendotheli
collagen
tissu
factor
captur
factor
vii
circul
initi
coagul
fibrin
format
stabil
primari
platelet
plug
form
blood
clot
either
local
occlud
blood
vessel
embol
occlud
narrow
vessel
downstream
case
manifest
clinic
symptom
mi
stroke
thought
intraplaqu
microvessel
contribut
unstabl
plaqu
phenotyp
mainli
deriv
vasa
vasorum
angiogen
sprout
follow
ingrowth
lesion
recent
rademak
et
al
demonstr
plaqueassoci
vasa
vasorum
angiogen
activ
albeit
poorli
perfus
moreov
plaqueassoci
vasa
vasorum
show
increas
permeabl
reduc
blood
flow
increas
leukocyt
adhes
extravas
characterist
could
contribut
plaqu
progress
destabil
imag
plaqueangiogenesi
could
ascertain
exact
import
intraplaqu
angiogenesi
predict
plaqu
growth
ruptur
angiogenesi
involv
complex
interplay
growth
factor
adhes
molecul
extracellular
matrix
activ
endotheli
cell
present
angiogen
blood
vessel
express
marker
minim
express
complet
absent
normal
blood
vessel
biomark
includ
integrin
v
b
v
b
certain
receptor
vascular
growth
factor
matrix
metalloproteas
mmp
aminopeptidas
n
apn
also
call
receptor
zinc
depend
membranebound
ectopeptidas
identifi
import
regul
endotheli
morphogenesi
angiogenesi
bind
peptid
protein
expos
tripeptid
asparagineglycinearginin
ngr
amino
acid
residu
motif
emerg
recur
sequenc
phage
display
experi
direct
b
integrin
also
surfac
phage
display
experi
v
b
integrin
select
express
angiogenesi
serv
target
molecular
imag
tracer
noninvas
visual
angiogen
process
vivo
noninvas
determin
express
potenti
use
monitor
treatment
respons
proor
antiangiogen
drug
tumor
ischem
heart
diseas
respect
paper
discuss
target
discoveri
peptid
ligand
ngr
motif
ngrisodgr
molecular
switch
design
develop
ngrbase
imag
probe
overview
imag
studi
cyclic
ngrbase
tracer
cancer
cardiovascular
diseas
given
search
b
bind
ligand
koivunen
et
al
found
besid
variou
rgdcontain
peptid
ngrcontain
peptid
ngraha
repres
b
bind
sequenc
addit
isol
ngrcontain
peptid
upon
screen
cyclic
peptid
phage
librari
similar
experiment
condit
vivo
select
phage
display
librari
use
isol
peptid
home
specif
tumor
blood
vessel
cngrcvsgcagrcphag
demonstr
target
tumor
vasculatur
nude
mice
bear
human
breast
carcinoma
linear
ngrahaand
cyclic
cvlngrmecpeptid
previous
identifi
vitro
also
select
local
tumor
coinject
cngrcvsgcagrc
ngrahaor
cvlngrmecphag
cngrc
peptid
cy
cy
disulfid
inhibit
accumul
phage
breast
cancer
xenograft
indic
function
tumor
target
peptid
anoth
tumor
target
peptid
discov
phage
displaybas
studi
acdcrgdcfc
bind
v
b
v
b
integrin
express
sprout
endotheli
cell
ngrcontain
peptid
bind
integrin
although
lower
affin
rgd
peptid
crossinhibit
experi
tumor
home
could
inhibit
free
peptid
wherea
free
peptid
could
partial
compet
tumor
home
result
suggest
bind
distinct
receptor
soon
found
receptor
ngrcontain
peptid
although
appear
major
target
ngr
contain
peptid
larg
differ
ngr
bind
among
isoform
ngr
peptid
preferenti
bind
endotheli
cell
small
angiogen
vessel
much
lesser
extent
posit
larg
blood
vessel
express
macrophag
may
due
differenti
util
oglycosyl
site
among
isoform
conform
chang
induc
isoform
due
complex
proangiogen
protein
unidentifi
compound
structur
aminopeptidas
n
broad
specif
aminopeptidas
prefer
neutral
amino
acid
occur
solubl
membranebound
form
multipl
distinct
glycoform
report
structur
amino
acid
long
human
protein
yet
resolv
howev
membranebound
form
protein
known
occur
noncoval
homodim
rel
molecular
mass
kda
monom
consist
short
ntermin
cytoplasmat
domain
singl
transmembran
domain
larg
glycosyl
extracellular
domain
contain
aminopeptidas
activ
site
addit
membranebound
form
solubl
also
report
plasma
urin
mani
function
ascrib
divid
three
group
enzymat
cleavag
peptid
endocytosi
signal
transduct
recent
review
minaosorio
peptidas
remov
ntermin
amino
acid
oligopeptid
except
peptid
contain
pro
penultim
posit
amino
acid
substrat
order
prefer
determin
ala
phe
tyr
leu
arg
thr
trp
ly
ser
asp
val
known
peptid
substrat
includ
enkephalin
kinin
hemorphin
neuropeptid
vasoact
angiotensin
immunomodulatori
tetrapeptid
tuftsin
chemotact
peptid
monocyt
chemotact
protein
nformylmethionylleucylphenylalanin
addit
human
viral
receptor
number
virus
includ
human
coronaviru
possibl
also
human
cytomegaloviru
hcmv
function
shown
independ
catalyt
function
sinc
neither
activ
site
mutat
activ
site
inhibitor
affect
viru
bind
import
angiogenesi
discov
identifi
main
target
ngr
studi
mice
show
mice
suffer
decreas
retin
neovascular
hypox
condit
show
reduc
angiogen
respons
growth
factor
express
strongli
correl
invas
capac
number
tumor
cell
type
play
role
cell
differenti
motil
prolifer
apoptosi
membranebound
involv
phagocytosi
adhes
final
one
main
target
ezetimib
clinic
use
drug
hypercholesterolaemia
quit
remark
ngr
motif
discov
phage
display
search
integrin
binder
even
though
ngr
sequenc
littl
integrin
bind
affin
recent
observ
asparagin
residu
ngr
spontan
convert
isoaspart
result
isodgr
isodgr
mimic
rgd
motif
wellknown
integrin
bind
motif
asparagin
isoaspart
convers
known
protein
age
reaction
first
step
convers
nucleophil
attack
peptid
bond
nitrogen
adjac
amino
asparagin
side
chain
carbonyl
lead
format
cyclic
succinimid
intermedi
loss
one
molecul
ammonia
succinimid
intermedi
undergo
hydrolyt
ring
open
either
carbonyl
imid
ring
give
rise
aspart
isoaspart
isomer
also
occur
reaction
limit
extent
major
product
reaction
laspart
lisoaspart
typic
ratio
scheme
asparagin
isoaspart
convers
caus
quit
larg
local
chang
protein
sinc
caus
chang
charg
state
chang
protein
backbon
convers
aamino
acid
longer
bamino
acid
gener
convers
asparagin
aspart
take
hour
day
year
depend
number
factor
includ
protein
microenviron
ph
ionic
strength
temperatur
reaction
rate
ngr
isodgr
reaction
vari
well
typic
quit
rapid
hour
vitro
protein
age
reaction
caus
loss
function
ngr
isodgr
may
actual
gainoffunct
effect
fibronectin
four
ngr
motif
contain
sequenc
identifi
function
latent
v
b
integrin
bind
site
molecular
model
shown
isodgr
neatli
dock
onto
site
v
b
integrin
rgd
albeit
invert
orient
also
shown
isodgr
contain
peptid
bind
b
integrin
well
b
v
b
select
depend
flank
residu
ngrisodgr
motif
magnet
reson
imag
mri
power
noninvas
techniqu
visual
soft
tissu
anatomi
diagnosi
diseas
enhanc
contrast
weight
mr
imag
gadolinium
iii
gd
iii
chelat
commonli
use
mri
contrast
agent
sever
patho
fysiolog
process
angiogenesi
difficult
imag
mri
therefor
targetspecif
mri
contrast
agent
design
bind
marker
express
cell
involv
process
could
drastic
improv
imag
angiogenesi
due
accumul
contrast
agent
around
cell
explor
possibl
efficaci
achiev
multimod
multival
cyclicngr
construct
sever
approach
synthet
rout
explor
initi
fluoresc
monomod
construct
prepar
optic
imag
consist
cyclicngr
cngr
moieti
glyglyli
n
e
oregon
green
sequenc
ad
ctermin
therefor
acci
asn
xanthyl
glyarg
tosyl
cy
glyglyli
fmoc
synthes
tboc
tertbutyloxycarbonyl
solidphas
peptid
synthesi
spp
resin
fmoc
protect
group
lysin
remov
subsequ
oregon
green
coupl
lysin
eamino
group
deprotect
cleavag
peptid
resin
peptid
cycliz
format
intern
disulfid
bond
oxid
fold
unconjug
cngr
use
control
compound
compound
synthes
analog
though
acetyl
lysin
eamino
group
accysasnglyargcysglyglyli
ac
nh
gain
insight
target
process
cngr
bimod
fluoresc
mri
probe
base
gadolinium
iii
diethylenetriaminepentaacet
acid
gd
iii
dtpa
cngr
synthes
highli
effici
chemoselect
reaction
procedur
use
synthesi
bimod
targetspecif
contrast
agent
allow
imag
mri
optic
method
groundbreak
nativ
chemic
ligat
ncl
technolog
enabl
format
peptid
bond
ngr
peptid
cysteinefunction
dtpa
chelat
subsequ
free
thiol
introduc
cystein
use
conjug
maleimid
remov
acetamidomethyl
acm
protect
group
subsequ
oxid
fold
result
dtpaand
cyclicngr
peptid
scheme
multival
structur
becom
new
focu
investig
drug
design
chemic
biolog
multimer
compound
could
theoret
bind
multival
target
thu
avidli
target
cell
immobil
multipl
cyclic
ngr
moieti
mri
label
one
singl
carrier
bind
cngr
may
improv
cooper
bind
multival
result
stronger
accumul
mri
contrast
agent
around
region
angiogenesi
next
target
sensit
major
challeng
molecular
mr
imag
one
way
increas
contrast
connect
multipl
gd
iii
chelat
one
carrier
next
gener
construct
consist
tetramer
avidin
core
bound
four
ident
peptid
base
molecul
consist
cngr
part
biotin
dtpa
moieti
idea
increas
bind
avid
cooper
bind
increas
imag
sensit
local
increas
gd
iii
gadolinium
chelat
concentr
synthesi
construct
shown
scheme
briefli
synthesi
involv
tboc
spp
bissacm
protect
thioester
precursor
coupl
cystein
function
biotin
nativ
chemic
ligat
next
singl
free
thiol
ligat
site
react
maleimid
function
dtpa
molecul
stage
sacm
deprotect
simultan
disulfid
bond
format
could
safe
perform
without
risk
disulfid
shuffl
transthioesterif
final
gd
iii
chelat
fragment
mix
avidin
creat
tetraval
construct
addit
number
modifi
cngr
nanoparticlebas
contrast
agent
angiogenesi
imag
prepar
investig
time
evalu
nanoparticl
univers
scaffold
target
molecular
imag
multival
cngr
coat
quantum
dot
qd
compos
cdse
core
zn
shell
cover
qd
k
em
nm
k
em
nm
contain
surfacebound
streptavidin
allow
biotinyl
compound
bind
averag
qd
quantum
dot
like
appli
clinic
use
accumul
spleen
liver
constitut
facil
sensit
toolbox
test
combin
target
peptid
imag
modal
allow
multimod
detect
anim
model
well
cellular
local
use
multiphoton
laserscan
microscopi
fig
case
optim
combin
target
imag
moieti
tailor
organ
synthesi
contrast
agent
without
qd
yield
imag
agent
suitabl
clinic
translat
modular
natur
multival
construct
allow
ration
design
target
agent
imag
modal
instanc
chang
ratio
target
imag
moieti
construct
skew
toward
multival
bind
low
affin
target
multival
detect
low
abund
target
proof
concept
approach
biotinyl
cngr
peptid
biotinfunction
dendrit
dtpa
construct
develop
test
combin
qdscaffold
first
qd
k
em
nm
k
em
nm
load
noth
cngr
peptid
prepar
therefor
acci
asn
xanthyl
glyarg
tosyl
cy
glyglyli
fmoc
synthes
tboc
spp
describ
monomer
monoval
cngr
peptid
resin
remov
fmoc
protect
group
lysin
biotinsuccinimidyl
ester
coupl
lysinen
e
group
subsequ
peptid
simultan
deprotect
cleav
resin
purifi
oxid
fold
gener
intern
disulfid
bridg
cngr
coat
qd
gener
mix
qdstreptavidin
sixfold
molar
excess
cngrbiotin
ensur
multival
load
qd
cngr
poli
lysin
dendrit
dtpa
wedg
obtain
use
manual
solidphas
peptid
synthesi
first
step
spp
focal
point
wedg
defin
wherea
final
coupl
step
peripheri
determin
addit
function
introduc
focal
point
obtain
dtpafunction
wedg
gener
poli
lysin
dendrit
wedg
thioesterfunction
focal
point
sulfhydryl
group
along
peripheri
synthes
glycin
spacer
consist
glycin
residu
introduc
thioester
focal
point
poli
lysin
dendrit
wedg
creat
space
coupl
wedg
ligand
gener
wedg
use
without
purif
function
dtpa
use
maleimidefunction
dtpa
format
dtpagd
iii
complex
equiv
gdcl
ad
wedg
ph
qd
enabl
bind
multipl
cngr
peptid
multipl
dtpa
moieti
next
gener
molecular
imag
tracer
contain
cngr
peptid
also
dtpagd
iii
complex
henc
poli
lysin
dendrit
dtpa
wedg
moieti
gener
thioesterfunction
focal
point
util
cngrqd
target
tracer
visual
angiogenesi
investig
vivo
ex
vivo
studi
myocardi
infarct
mi
induc
male
mice
ligat
left
coronari
arteri
sham
surgeri
consist
procedur
without
tie
ligatur
multimer
bimod
quantum
dot
monomer
monomod
agent
could
success
use
identifi
area
heart
suffer
hypoxia
result
develop
angiogen
vessel
due
induc
myocardi
infarct
mice
compar
small
fluoresc
probe
multival
qd
conjug
found
latter
show
brighter
fluoresc
signal
persist
signal
found
express
vessel
healthi
myocardium
also
larger
vessel
cngrbase
probe
found
bind
preferenti
posit
small
vessel
angiogen
infarct
area
spontan
neovascular
angiogenesi
arteriogenesi
like
determin
prognosi
patient
coronari
arteri
diseas
make
promis
new
tool
cardiovascular
imag
toolbox
cd
se
contain
qd
use
studi
like
toxic
human
use
qd
scaffold
may
replac
nanoparticl
peptidelik
scaffold
especi
sinc
fluoresc
properti
qd
longer
requir
follow
valid
nanoparticlebiomark
probe
conjug
angiogenesi
import
process
tumor
grow
metastas
therefor
studi
possibl
use
cngr
peptid
conjug
paramagnet
quantum
dot
tumor
imag
cngrqd
mention
design
bimod
imag
vivo
mri
ex
vivo
twophoton
laser
scan
microscopi
tplsm
therebi
allow
valid
result
qd
conjug
biotinpoli
lysin
dendrit
dtpa
wedg
biotincngr
peptid
use
control
swiss
nunu
mice
subcutan
grow
tumor
human
colorect
adenocarcinoma
studi
vivo
mri
ex
vivo
tplsm
found
cngrconjug
qd
gave
threefold
higher
quantit
mri
contrast
tumor
rim
tumor
region
highest
angiogen
activ
compar
noncngrconjug
qd
fig
addit
cngrconjug
qd
bare
detect
muscl
tissu
indic
high
specif
angiogen
vessel
compar
regular
blood
vessel
final
tplsm
show
coloc
cngrconjug
qd
endotheli
cell
tumor
vasculatur
valid
bind
specif
initi
studi
follow
depth
studi
pharmacokinet
tumor
imag
properti
cngrqd
conjug
compar
two
pharmacokinet
model
distribut
cngrqd
found
two
compart
model
fit
best
observ
data
two
compart
model
compris
blood
space
endotheli
cell
surfac
addit
third
extravascularextracellular
compart
reveal
irrelevantli
low
extravas
paramet
therefor
neglect
interestingli
accumul
cngr
neg
qd
tumor
tissu
also
observ
probabl
due
easier
extravas
presenc
larg
intercellular
space
tumor
tissu
mri
offer
good
depth
tissu
penetr
good
resolut
addit
anatom
inform
coregist
function
molecular
inform
within
singl
imag
method
major
disadvantag
mri
compar
radiotrac
techniqu
positron
emiss
tomographi
pet
singl
photon
emiss
comput
tomographi
spect
lower
sensit
detect
target
agent
recent
chen
et
al
synthes
monomer
dimer
ngrcontain
peptid
resp
conjug
chelat
n
n
n
tetraacet
acid
dota
result
peptid
radiolabel
pet
isotop
cu
h
b
kev
evalu
vitro
vivo
vitro
experi
demonstr
stabl
enough
phosphatebuff
salin
pb
room
temperatur
mous
serum
h
remain
intact
h
incub
mous
serum
order
select
appropri
tumor
cell
line
target
receptor
express
level
human
fibrosarcoma
cell
human
colon
adenocarcinoma
cell
investig
western
blot
analysi
immunofluoresc
stain
show
receptor
highli
overexpress
cell
cell
bind
affin
cell
measur
within
low
nanomolar
rang
twofold
higher
nm
nm
respect
subsequ
vivo
studi
confirm
show
higher
tumor
uptak
better
tumor
retent
presum
due
bival
effect
increas
appar
molecular
size
suitabl
pet
probe
noninvas
detect
receptor
express
vivo
molecular
imag
advanc
continu
improv
imag
equip
technolog
also
design
power
probe
optim
vivo
biodistribut
imag
characterist
synthet
access
cngrcontain
mono
bi
multimod
imag
agent
visual
express
tumor
cardiovascular
diseas
establish
preclin
research
present
molecular
imag
tracer
includ
earli
noninvas
evalu
proand
antiangiogen
therapi
myocardi
infarct
solid
tumor
respect
futur
clinic
applic
would
patient
stratif
develop
individu
therapi
unless
state
otherwis
reagent
solvent
purchas
commerci
sourc
use
without
purif
h
nmr
c
nmr
spectra
record
k
varian
uniti
inova
mhz
spectromet
mhz
respect
chemic
shift
given
part
per
million
ppm
revers
phase
high
pressur
liquid
chromatographi
rp
hplc
perform
varian
pro
star
hplc
system
coupl
uvvi
detector
probe
nm
use
vydactm
protein
peptid
column
electrospray
ioniz
mass
spectrometri
esm
perform
perkin
elmer
pe
sciex
turbo
ionspray
determin
relax
time
mix
dual
echo
sequenc
perform
voxel
size
mm
gadolinium
content
determin
mean
induct
coupl
plasma
atom
emiss
spectroscopi
icpa
leeman
lab
echel
spectromet
synthesi
acc
acm
ngrc
acm
ggmpalnh
manual
solid
phase
peptid
synthesi
spp
use
situ
hexafluorophosph
hbtu
activ
procedur
boc
chemistri
mbha
resin
describ
earlier
et
al
appli
synthes
peptid
contain
targetspecif
ngr
sequenc
ctermin
thioester
esm
calcd
c
cysteinefunction
dtpa
synthon
synthes
accord
literatur
procedur
mg
mmol
dissolv
ml
tri
aq
ph
ph
solut
adjust
ph
addit
small
aliquot
naoh
aq
subsequ
ad
mg
mmol
reaction
mixtur
shaken
dissolv
reaction
continu
h
room
temperatur
reaction
monitor
revers
phase
hplc
column
gradient
mecn
h
tfa
min
show
reaction
went
complet
reaction
mixtur
use
next
reaction
step
without
intermedi
purif
accngrcggc
gd
iii
dtpa
disulfid
mg
mmol
dissolv
ml
h
ph
adjust
ph
ad
small
aliquot
nh
oh
aq
solut
ad
ml
mm
solut
gdcl
h
equiv
mmol
done
stepwis
manner
monitor
esm
ensur
full
complex
thu
tumor
muscl
tissu
mice
inject
cngrlabel
unlabel
pqd
n
group
chang
r
pronounc
tumor
rim
cngrpqd
although
r
increas
tumor
rim
also
observ
unlabel
pqd
averag
respons
threefold
lower
compar
cngrpqd
indic
high
specif
cngr
angiogen
tumor
endothelium
support
low
chang
r
found
muscl
tissu
chang
b
coloc
almost
complet
chang
r
cbiotin
synthes
accord
literatur
procedur
acc
acm
ngrc
acm
ggcbiotin
mg
mmol
equiv
mg
mmol
dissolv
ml
guanidin
tri
aq
solut
v
thiophenol
v
benzylmercaptan
ad
ph
adjust
ph
addit
small
aliquot
naoh
aq
reaction
continu
h
reaction
mixtur
filter
product
purifi
prepar
rp
hplc
column
gradient
mecn
tfa
min
freez
dri
render
mg
mmol
fluffi
white
powder
esim
calcd
c
maldtpa
synthesi
publish
elsewher
acc
acm
ngrc
acm
ggc
dtpa
biotin
mg
mmol
dissolv
ml
tri
aq
ph
solut
ad
mg
mmol
ph
solut
adjust
ph
addit
small
aliquot
naoh
aq
reaction
continu
h
room
temperatur
reaction
monitor
complet
analyt
rp
hplc
column
gradient
mecn
tfa
min
reaction
mixtur
use
next
reaction
step
without
intermedi
purif
